Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "ključne besede" (treatment) .

1 - 10 / 69
Na začetekNa prejšnjo stran1234567Na naslednjo stranNa konec
1.
Cannabinoids and triple-negative breast cancer treatment
Luka Dobovišek, Simona Borštnar, Nataša Debeljak, Simona Kranjc Brezar, 2024, pregledni znanstveni članek

Povzetek: Triple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC were limited to chemotherapy. A new successful systemic treatment is immunotherapy with immune checkpoint inhibitors, but new tumor-specific biomarkers are needed to improve patient outcomes. Cannabinoids show antitumor activity in most preclinical studies in TNBC models and do not appear to have adverse effects on chemotherapy. Clinical data are needed to evaluate efficacy and safety in humans. Importantly, the endocannabinoid system is linked to the immune system and immunosuppression. Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy. In this article, we provide an overview of the currently available information on how cannabinoids may influence standard therapy in TNBC.
Ključne besede: triple-negative breast cancer, breast cancer, cancer treatment, cannabinoids
Objavljeno v DiRROS: 18.09.2024; Ogledov: 147; Prenosov: 75
.pdf Celotno besedilo (1,03 MB)
Gradivo ima več datotek! Več...

2.
1st Net4Brain Annual Meeting : Closing the translational gap in brain cancer treatment
2024, druge monografije in druga zaključena dela

Ključne besede: brain cancer, treatment, cytology, cancer biology, oncology, conferences
Objavljeno v DiRROS: 02.09.2024; Ogledov: 126; Prenosov: 867
.pdf Celotno besedilo (2,43 MB)

3.
Fenton-like photocatalyzed degradation of dibutyl phthalate with goethite and carboxylic acids
S. Hejdai, D. Buzek, Petr Klusoň, Oliver Bajt, 2023, izvirni znanstveni članek

Povzetek: Detailed investigation of photocatalyzed degradation of dibutyl phthalate (DBP), an endocrine disrupter, in the presence of α-FeOOH (goethite) and different carboxylic acids is the focus of this study. To get a better insight into the efficiency of the degradation, the influence of different parameters, such as concentration of total Fe and Fe(II), dissolved oxygen, DBP concentration, pH and salinity is investigated. The reaction mechanism consists of several interrelationship steps. The first step is the chemical reaction of carboxylic acid groups of the organic acids with hydroxyl groups of the α-FeOOH and a charge transfer upon illumination generating Fe(II). The second step is the release of Fe(II) into the solution followed by H2O2 oxidation to form highly photoactive hydroxyl complex of iron(III) and ˙OH. Simultaneously, the superoxide radical O2˙− and hydroperoxyl radical is formed in acidic solutions in presence of carboxylic acids as well. This mechanism explains the genesis of different reactive species oxidizing DBP. From the variety of the studied carboxylic acids (oxalic, citric, salicylic, pyruvic, maleic, and fumaric), oxalic acid is the best Fe-ligand for the photoreductive dissolution of goethite. Concentrations of the total amount of Fe and its dissociated forms Fe(II) as well as oxygen and hydroxyl radicals play a fundamental role in efficiency of DBP degradation. The photodegradation of DBP with goethite and the use of suitable carboxylic acids under optimized reaction conditions could be an efficient process for decontamination of polluted waters.
Ključne besede: photocatalysis, goethite, dibutyl phthalate, carboxylic acid, water treatment
Objavljeno v DiRROS: 31.07.2024; Ogledov: 256; Prenosov: 213
.pdf Celotno besedilo (1,42 MB)
Gradivo ima več datotek! Več...

4.
The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RASwild-type tumour (wtRAS) : a real- life data report 2013–2018
Tanja Mesti, Martina Reberšek, Janja Ocvirk, 2023, izvirni znanstveni članek

Povzetek: Background. We preformed a Phase IV non-interventional study to assess KRAS, NRAS and BRAF status in metastatic colorectal cancer (mCRC) patients suitable for 1st line treatment and to evaluate the decisions for 1st line treatment considering the treatment goals in the RAS wild type (wt) patients. The aim of our study was also to evaluate the influ-ence of a waiting period for biomarkers analysis on the start of first-line treatment.Patients and methods. Patients with histologically confirmed mCRC adenocarcinoma suitable for first-line treat-ment fulfilling all inclusion criteria were included in the study. The KRAS, NRAS and BRAF analysis was performed from tissue samples of primary tumor site or metastatic site. All included patients have given consent to participate in the study by signing the informed consent form. Results. From April 2013 to March 2018 at the Institute of Oncology Ljubljana 650 patients were included, 637 of them were treated with first- line systemic treatment according to RAS and BRAF status. Remaining 13 patients with mCRC did not receive systemic first-line treatment. The distribution of patients with KRAS mutated and wild-type tumors, was almost equal, 48.8% and 47.9% respectively, 89 % of the patients had wt NRAS tumours and 86.1% had wt BRAF tu-mours. The most frequently prescribed treatment was bevacizumab-based therapy (53.1%), either in combination with doublet chemotherapy or with mono-chemotherapy. EGFR inhibitors cetuximab and panitumumab were prescribed in wt RAS mCRC patients (30.9%). The waiting period for biomarkers analysis was two weeks.Conclusions. Our real-world data, single centre 5-year analysis showed that the distribution between wild type and mutated type tumors of the patients with mCRC was approximately the same, as worldwide, so the Slovenian popula-tion with mCRC has the same ratio distribution of KRAS, NRAS and BRAF wild and mutated genes. We concluded that a two-week waiting period for biomarkers analysis did not influence the first line treatment decision, so it was in the accordance with the worldwide treatment guidelines based on evidence-based medicine.
Ključne besede: metastatic colorectal cancer, RAS and BRAF biomarkers, systemic treatment
Objavljeno v DiRROS: 25.07.2024; Ogledov: 220; Prenosov: 90
.pdf Celotno besedilo (367,23 KB)

5.
Surgical treatment and fertility perservation in endometrial cancer
Nina Kovačević, 2021, pregledni znanstveni članek

Povzetek: Endometrial cancer (EC) represents a high health burden in Slovenia and worldwide. The incidence is increasing due to lifestyle and behavioural risk factors such as obesity, smoking, oestrogen exposure and aging of the population. In many cases, endometrial cancer is diagnosed at an early stage due to obvious signs and symptoms. The standard treatment is surgery with or without adjuvant therapy, depending on the stage of the disease and the risk of recurrence. However, treatment modalities have changed in the last decades, considerably in the extent of lymphadenectomy. Conclusions. The gold standard of treatment for is surgery, which may be the only treatment modality in the early stages of low-grade tumours. In recent years, a minimally invasive approach with sentinel node biopsy (SNB) has been proposed. A conservative approach with hormonal treatment is used if fertility preservation is desired. If EC is in advance stage, high-risk histology, or high grade, radiotherapy, chemotherapy, or a combination of both is recommended.
Ključne besede: endometrial cancer, uterus, treatment, minimally invasive surgery
Objavljeno v DiRROS: 22.07.2024; Ogledov: 223; Prenosov: 55
.pdf Celotno besedilo (252,84 KB)

6.
Completely resected stage III melanoma controversy : 15 years of national tertiary centre experience
Barbara Perić, Sara Milićević, Andraž Perhavec, Marko Hočevar, Janez Žgajnar, 2021, izvirni znanstveni članek

Povzetek: Background Two prospective randomized studies analysing cutaneous melanoma (CM) patients with sentinel lymph node (SLN) metastases and rapid development of systemic adjuvant therapy have changed our approach to stage III CM treatment. The aim of this study was to compare results of retrospective survival analysis of stage III CM patients% treatment from Slovenian national CM register to leading international clinical guidelines. Patients and methods Since 2000, all Slovenian CM patients with primary tumour % TIb are treated at the Institute of Oncology Ljubljana and data are prospectively collected into a national CM registry. A retrospective analysis of 2426 sentinel lymph node (SLN) biopsies and 789 lymphadenectomies performed until 2015 was conducted using Kaplan-Meier survival curves and log-rank tests. Results Positive SLN was found in 519/2426 (21.4%) of patients and completion dissection (CLND) was performed in 455 patients. The 5-year overall survival (OS) of CLND group was 58% vs. 47% of metachronous metastases group (MLNM) (p = 0.003). The 5-year OS of patients with lymph node (LN) metastases and unknown primary site (UPM) was 45% vs. 21% of patients with synchronous LN metastasis. Patients with SLN tumour burden < 0.3 mm had 5-year OS similar to SLN negative patients (86% vs. 85%; p = 0.926). The 5-year OS of patients with burden > 1.0 mm was similar to the MLNM group (49% vs. 47%; p = 0.280). Conclusions Stage III melanoma patients is a heterogeneous group with significant OS differences. CLND after positive SLNB might still remain a method of treatment for selected patients with stage III.
Ključne besede: cutaneous melanoma, surgery treatment, sentinel node biopsy
Objavljeno v DiRROS: 17.07.2024; Ogledov: 260; Prenosov: 113
.pdf Celotno besedilo (406,28 KB)
Gradivo ima več datotek! Več...

7.
Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe
Milada Zemanova, Marko Jakopović, Karmen Stanič, Małgorzata Łazar-Poniatowska, Martina Vrankar, Petronela Rusu, Tudor Ciuleanu, Davorin Radosavljevic, Krisztina Bogos, Sergiusz Nawrocki, 2020, izvirni znanstveni članek

Povzetek: The aim of this project was to collect real-world evidence and describe treatment patterns for stage III non-small cell lung cancer in Central and Eastern Europe. Based on real-world evidence, an expert opinion was developed, and the unmet needs and quality indicators were identified. Patients and methods. A systematic literature search and a multidisciplinary expert panel of 10 physicians from 7 countries used a modified Delphi process to identify quality indicators and unmet needs in patients with stage III non-small cell lung cancer. The profound questionnaire was used to characterize treatment patterns used for stage III non-small cell lung cancer, and a systematic review identified patterns in Central and Eastern Europe. The first questionnaire was completed by a group of medical oncologists, radiation oncologists and pneumologists. The panel of experts attended an in-person meeting to review the results of the questionnaire and to process a second round Delphi. An additional survey was then compiled and completed by the panel. Results. A complete consensus was reached by the panel of experts on a set of evidence-based clinical recommendations. The experience-based questionnaire generated a highly variable map of treatment patterns within the region. A list of unmet needs and barriers to quality care were developed with near-unanimous consent of the panel of experts. Conclusions. The current landscape of diagnostic and therapeutic approaches in Central and Eastern European countries is highly variable. We identified several significant barriers, mainly related to the availability of diagnostic and imaging methods and low rates of chemoradiotherapy with curative intention as initial treatment for unresectable stage III NSCLC.
Ključne besede: non-small cell lung cance, stage III, treatment patterns, Delphi method
Objavljeno v DiRROS: 16.07.2024; Ogledov: 270; Prenosov: 105
.pdf Celotno besedilo (298,89 KB)
Gradivo ima več datotek! Več...

8.
Percutaneous mechanical thrombectomy in patients with high-risk pulmonary embolism and contraindications for thrombolytic therapy
Matjaž Bunc, Klemen Steblovnik, Simona Kržišnik-Zorman, Peter Popović, 2020, izvirni znanstveni članek

Povzetek: Background. High-risk pulmonary embolism is associated with a high early mortality rate. We report our experience with percutaneous mechanical thrombectomy in patients with high-risk pulmonary embolism and contraindications for thrombolytic therapy.Patients and methods. This was a retrospective analysis of consecutive patients with high-risk pulmonary embolism and contraindications to thrombolytic therapy. They were treated with percutaneous mechanical thrombectomy which included thrombectomy and additional thrombus aspiration when needed. Clinical parameters and survival to discharge were measured. Results. From November 2005 to September 2015 we treated 25 patients with a mean age of 62.6 +- 12.7 years, 64% were men. Mean simplified Pulmonary Embolism Severity Index was 2.9. Mean maximum lactate levels were 7.8 +- 6.6 mmol/L, vasopressors were used in 77%, and 59% needed mechanical ventilation. Mechanical treatment included thrombus fragmentation complemented with aspiration (56%) and aspiration using Aspirex S catheter (44%). Local (5 patients; 20%) and systemic (3 patients; 12%) thrombolytics were used as a salvage therapy. We observed nonsignifi-cant improvements in systemic blood pressure (100 +- 41 mm Hg vs 119 +- 34; p = 0.100) and heart frequency (99 +- 35 min-1vs 87 +- 31 min-1; p = 0.326) before and after treatment, respectively. Peak systolic tricuspid pressure gradient was significantly lower after treatment (57 +- 14 mm Hg vs 31 +- 3 mm Hg; p = 0.018). Overall the procedure was technically successful in 20 patients (80%) and 17 patients (68%) survived to hospital discharge. Conclusions. In patients with high-risk pulmonary embolism who cannot receive thrombolytic therapy, percutaneous mechanical thrombectomy is a promising alternative to reduce pulmonary artery pressure.
Ključne besede: high-risk pulmonary embolism, treatment, percutaneous mechanical thrombectomy
Objavljeno v DiRROS: 16.07.2024; Ogledov: 264; Prenosov: 148
.pdf Celotno besedilo (554,75 KB)
Gradivo ima več datotek! Več...

9.
Modern treatment of vulvar cancer
Sebastjan Merlo, 2020, pregledni znanstveni članek

Povzetek: Vulvar cancer accounts for 3%5% of malignant diseases of the female genital tract. The Slovenian incidence rate is 5.5/100,000, which means 57 new cases per year. The most common histological type (90%) is squamous cell carcinoma. Based on etiology, it can be classified into the first type which correlates with human papillomavirus (HPV) infection and the second type which is not associated with HPV. The most common and long-lasting symptom of vulvar cancer is pruritus. The preferred diagnostic procedure to confirm the diagnosis is a punch or incision biopsy. Surgery in combination with radiotherapy is the standard treatment for vulvar cancer. Sentinel lymph node biopsy with lymphoscintigraphy is now a standard part of surgical treatment. Chemotherapy is a palliative treatment option. Conclusions. Vulvar cancer is a rare disease. Because of the pathogenesis, surgery and radiotherapy are the main treatment modalities. The sentinel node biopsy (SNB) represents a contemporary approach to the vulvar cancer treatment and significantly reduces morbidity. Improvements in treatment of vulvar cancer contributed to the decrease of mortality among Slovenian women.
Ključne besede: vulvar cancer, surgical treatment, sentinel lymph node biopsy, lymphoscintigraphy
Objavljeno v DiRROS: 16.07.2024; Ogledov: 224; Prenosov: 52
.pdf Celotno besedilo (235,46 KB)

10.
Iskanje izvedeno v 0.29 sek.
Na vrh